Skip to main content

ETNB

Stock
Health Care
Biotechnology

Performance overview

ETNB Price
Price Chart

Forward-looking statistics

Beta
1.07
Risk
78.55%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

Company info

SectorHealth Care
IndustryBiotechnology
Employees57
Market cap$796.9M

Fundamentals

Enterprise value$832.4M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity6.21

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$3.46
Dividend per share
Revenue per share
Avg trading volume (30 day)$21M
Avg trading volume (10 day)$18M
Put-call ratio

Macro factor sensitivity

Growth+4.6
Credit+2.5
Liquidity-4.3
Inflation+6.4
Commodities+2.7
Interest Rates-1.6

Valuation

Dividend yield0.00%
PEG Ratio-3.54
Price to sales
P/E Ratio-3.54
Enterprise Value to Revenue
Price to book2.45

Upcoming events

Next earnings dayMay 2, 2025
Next dividend day
Ex. dividend day

News

Bears are Losing Control Over 89BIO (ETNB), Here's Why It's a 'Buy' Now

89BIO (ETNB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Investment Research (March 12, 2025)
This Analyst Thinks 89Bio's Pegozafermin Data Has Exceeded Expectations

In June, 89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe hypertriglyceridemia (SHTG).  SVB Leerink views these results as 'strong' and says they provide a clear win for the company as.

Benzinga (July 11, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free